Clinical trials
Graft Versus Host Disease clinical trials
Below are recruiting graft versus host disease clinical trials, each written for real people, not researchers. We’re tracking 120 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07127926RecruitingPhase 1
Belumosudil pill vs crushed pill study for chronic GVHD
This trial tests whether crushing belumosudil tablets changes how the drug works in people with chronic graft-versus-host-disease (GVHD), a complication after a stem cell transplant. It helps doctors know if taking crushed pills is as effective as whole tablets.
Houston, TexasAges 18 years+ - NCT07776210RecruitingPhase 3
Eye drops for chronic dry eye after stem cell transplant
This trial tests an eye drop solution for people with chronic dry eye caused by graft-versus-host disease after a stem cell transplant. It aims to see if the drops can reduce eye discomfort and improve the eye surface.
Beverly Hills, CaliforniaAges 18 years+ - NCT06649201Recruiting
Study of vaginal health after stem cell transplant
This study looks at how stem cell transplants affect the vagina, especially if you develop a condition called graft-versus-host disease (GVHD). Researchers will examine the vagina and test its natural germs (microbiome) to better understand and possibly improve treatment.
Cleveland, OhioAges 18–70 - NCT06300320RecruitingPhase 2
TQ05105 for chronic graft-versus-host disease
This trial is testing an investigational drug called TQ05105 for people with moderate to severe chronic graft-versus-host disease (GVHD) after a stem cell transplant. It may offer a new treatment option if current therapies are not working well enough.
Hefei, AnhuiAges 18–70 - NCT07124078RecruitingPhase 2
Study of axatilimab for young people with chronic graft-versus-host disease
This study tests a new drug called axatilimab for children and teens with chronic graft-versus-host disease (cGVHD) that hasn't improved with standard treatments. The goal is to see if axatilimab works better than the usual care options. Participants will be randomly assigned to receive either axatilimab or one of several standard treatments.
Duarte, CaliforniaAges 2–17 - NCT06294691RecruitingPhase 3
Timing of stem cell infusion to prevent GVHD in blood cancer
This study is testing whether the timing of a stem cell infusion affects the chance of developing graft-versus-host disease (aGVHD), a common complication after transplant. It may help make transplants safer for people with blood cancers.
Hefei, AnhuiAges 12–60 - NCT07166848Enrolling by invitation
Electrical stimulation study for dry eye from graft vs. host disease
This trial tests if gentle electrical stimulation around the eye can help relieve dry eye symptoms caused by chronic graft versus host disease (a complication after a stem cell or bone marrow transplant). It is for people with moderate to severe dry eye who have not had recent eye surgeries or certain other eye problems.
Boston, MassachusettsAges 18–75 - NCT07246031RecruitingPhase 2
BPC2001 to Prevent Graft-Versus-Host Disease After Stem Cell Transplant
This trial tests a new drug, BPC2001, to see if it can prevent graft-versus-host disease (a common complication where donor cells attack the patient's body) in people receiving a half-matched stem cell transplant from a family donor. It may be an option for adults with certain blood cancers who are planning their first transplant.
Beijing, Beijing MunicipalityAges 18–65 - NCT07011810RecruitingPhase 2
Axatilimab for sclerotic chronic graft-versus-host disease
This study tests a new drug called axatilimab for people with a specific type of chronic graft-versus-host disease (cGVHD) that causes hardening or thickening of the skin or joints. cGVHD is a complication after a stem cell transplant where the donor's immune cells attack your body. The study aims to see if axatilimab can improve these sclerotic symptoms. If you have this condition and it was recently diagnosed (within the last year), you might qualify to participate.
Tampa, FloridaAges 18 years+ - NCT07535008Recruiting
Dental Cleaning to Prevent Graft-Versus-Host Disease
This study tests whether professional dental cleaning after a stem cell transplant can help prevent chronic graft-versus-host disease (GVHD), a condition where transplanted immune cells attack your body. You'll receive dental cleanings and be followed for one year to see if this simple preventive step reduces GVHD complications.
Seattle, WashingtonAges 18 years+ - NCT05470491RecruitingPhase 1/Phase 2
Haploidentical bone marrow transplant with GVHD prevention drugs
This trial tests a reduced-intensity bone marrow transplant from a related donor (haploidentical), using medicines to help prevent a serious complication called GVHD. It is for people with certain blood cancers and aims to improve outcomes by balancing transplant benefit with lower treatment intensity.
Bethesda, MarylandAges 12–120 - NCT06585774RecruitingPhase 3
Axatilimab plus steroids for new chronic GVHD
This study tests a new drug called axatilimab combined with steroids as a first treatment for chronic graft-versus-host disease (GVHD) after a stem cell transplant. It aims to see if this combination helps control symptoms better than steroids alone.
Birmingham, AlabamaAges 12 years+ - NCT06936566RecruitingPhase 2
Ruxolitinib for graft-versus-host disease after transplant
This trial tests a drug called ruxolitinib for treating acute graft-versus-host disease (aGVHD), a common complication after a stem cell transplant. It may help control the immune reaction without using high doses of steroids.
Duarte, CaliforniaAges 18 years+ - NCT06657391RecruitingPhase 2
Study of a new drug to prevent graft-versus-host disease in thalassemia patients
This trial tests a drug called an anti-CD25 antibody to see if it can prevent graft-versus-host disease (a condition where donor cells attack the body) in people with transfusion-dependent thalassemia who are getting a stem cell transplant from a partially matched or unrelated donor.
Maoming, GuangdongAges 3–20 - NCT06343792RecruitingPhase 2
Testing RLS-0071 for steroid-resistant acute graft-versus-host disease
This trial tests a new drug, RLS-0071, for people who are hospitalized with acute graft-versus-host disease that hasn't improved with steroids. It aims to see if the drug is safe and can help control the condition.
Duarte, CaliforniaAges 12 years+ - NCT05921305RecruitingPhase 3
Low-dose methotrexate plus steroid for early acute GVHD
This Phase 3 trial tests whether a specific low-dose medication (methotrexate) together with standard steroid treatment can improve early outcomes in patients with acute graft-versus-host disease after a stem cell transplant. It may help control the immune reaction that attacks the body after transplant.
Beijing, Beijing MunicipalityAges 15–65 - NCT05443425RecruitingPhase 1
Leflunomide plus steroids for acute graft-versus-host disease
This early-phase trial tests whether adding leflunomide to standard steroid treatment can better control acute graft-versus-host disease (aGvHD) after a stem cell transplant. It may help reduce the immune reaction that damages the body while keeping treatment safe and manageable.
Duarte, CaliforniaAges 18 years+ - NCT04629833RecruitingPhase 3
Mesenchymal cells vs standard care for steroid-resistant graft-versus-host disease
This trial studies a type of immune-support cell therapy (mesenchymal stromal cells) compared with the best available standard treatment for acute graft-versus-host disease (aGvHD) that does not respond to steroids. It may help by calming an overactive immune reaction after a stem cell transplant.
AmiensAges 12 years+ - NCT03819803RecruitingPhase 3
Fecal transplant for gut graft-versus-host disease
This study tests whether restoring healthy gut bacteria using a fecal microbiota transplant can improve steroid-refractory gut graft-versus-host disease (aGvHD) after stem cell transplant. If your gut symptoms are your first episode and your stool bacteria diversity is low, this trial may be an option worth screening for.
Graz, StyriaAges 18–70 - NCT03148743Recruiting
Fecal transplant for gut graft-versus-host disease
This study tests whether a fecal transplant (FMT) can help treat gut graft-versus-host disease (gut GVHD), a condition where donated immune cells attack the intestines. If you have gut GVHD and meet age requirements, you may be eligible to receive this treatment in the trial.
Suzhou, JiangsuAges 10–60 - NCT06750133RecruitingPhase 1
CNK-UT cell therapy for steroid-resistant graft-versus-host disease
This trial tests a new cell therapy called CNK-UT for people with severe graft-versus-host disease (aGVHD) that hasn't improved with steroid treatment after a stem cell transplant. The goal is to see if it can help control the immune reaction.
Fuzhou, FujianAges 14–70 - NCT05718791Recruiting
Testing blood markers to predict graft-versus-host disease
This trial looks at two blood markers to predict the risk of acute graft-versus-host disease after an allogeneic stem cell transplant. If you qualify, your care team may use results to help anticipate and manage complications earlier.
Detroit, MichiganAges 18–80 - NCT06321198Recruiting
Modified stem cells for severe graft-versus-host disease
This trial tests a new type of stem cell therapy (iMSC) for people with steroid-resistant acute graft-versus-host disease (aGVHD), a serious complication after a stem cell transplant. The goal is to see if it's safe and might help control the disease.
Hefei, AnhuiAges 4–70 - NCT07070674RecruitingPhase 1
Study of AC-003 for steroid-resistant graft-versus-host disease
This trial tests an experimental capsule (AC-003) for people with graft-versus-host disease (aGVHD) after a stem cell transplant, whose aGVHD did not get better with steroids. The goal is to see if it can help control the condition.
Tianjin, Tianjin MunicipalityAges 18 years+
Hear when a new Graft Versus Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Graft Versus Host Disease trials by city
Studies with a site in or near these metro areas.
Graft Versus Host Disease trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for graft versus host disease?
- Yes. Clin2 currently lists 120 recruiting graft versus host disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a graft versus host disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a graft versus host disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.